Royalty Report: Drugs, Disease, Therapeutic – Collection: 7014


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7014

License Grant
The Israeli Licensee has in-licensed rights from the Israeli Licensors with respect to our BL-1020 and BL-1021 therapeutic candidates.

In June 2010, the Israeli Licensee entered into an exclusive, royalty-bearing out-licensing arrangement with Cypress Bioscience with regard to BL-1020, covering the United States, Canada and Mexico, which became effective in August 2010. The Licensee received an upfront fee of $30.0 million from Cypress Bioscience upon the effectiveness of the agreement.

Field of Use
The Licensee is obligated to pay to the Licensor, collectively, a royalty payment on the net consideration received from the out-licensing of BL-1020.

BL-1020 is for the treatment of schizophrenia.

IPSCIO Record ID: 6748

License Grant
The Licensor of Israel entered into an exclusive, royalty-bearing out-licensing arrangement with the Licensee, for BL-1020, covering the United States, Canada and Mexico. Under the arrangement, the Licensee is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize, BL-1020 for the prevention, diagnosis and treatment of all human diseases in the United States, Canada and Mexico. The Licensor has retained the rights to BL-1020 for the rest of the world. In addition, the Licensee has Licensed to us the right to use any and all regulatory data generated by the Licensee in connection with its pursuit of regulatory approval for BL-1020 in the Licensee's territory, for use by us outside of Licensee's territory, subject to our future reimbursement of certain pre-commercialization expenses incurred by Licensee in generating such data.
License Property
BL-1020, a new chemical entity, may be the first antipsychotic therapeutic to improve cognitive function in schizophrenia patients. BL-1020 targets the imbalance of two key neurotransmitters implicated in schizophrenia, dopamine and gamma aminobutyric acid, or GABA. We believe that the reduction in psychotic symptoms is attributable to BL-1020’s dopamine antagonism. BL-1020’s GABAergic activity may improve cognition.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 7006

License Grant
In January 2011, Royalty Pharma acquired the Licensor. After the acquisition, the Licensee had a number of discussions with the Licensor and Royalty Pharma and they indicated to the Licensee that as a result of a change in their strategy, they believed it was in the best interest of BL-1020’s future commercial potential to consolidate the worldwide rights with the Licensee.
Field of Use
The Licensee believes that reacquiring BL-1020 was the best alternative at that time to ensure the timely development of BL-1020.

BL-1020 for the treatment of schizophrenia is one of the Licensee's lead therapeutic candidates in clinical development. BL-1020 for the treatment of schizophrenia.

IPSCIO Record ID: 203252

License Grant
The Israeli Licensor grants an exclusive, even as to Licensor, a license under the Licensor Technology, to Pre-Commercialize, use, sell, offer for sale, have sold, import and otherwise Commercialize the Products in the Field in the Licensees Territory, to make and have made Products for Commercialization in the Territory; and further provided that Licensor retains all rights to make and have made Products, and to license manufacture of Products, outside of the Licensees Territory;
and a non-exclusive license, with the right to grant sublicenses, through multiple tiers, under Product Inventions, to use any Product Inventions for the pre-commercialization, manufacture and commercialization of products other than the Products in the Licensee Territory;
and an exclusive license, with the right to grant sublicenses, through multiple tiers, to use Licensor Regulatory Data to Pre-Commercialize, Commercialize or manufacture the Products in the Licensee Territory, including the right to use any and all such Licensor Regulatory Data in any Regulatory Filings.
License Property
The product is BL-1020 in any dosage form or formulation or mode of administration, alone or in combination with other therapeutically active ingredients.  It is a first in class antipsychotic that combines dopamine antagonism with GABAergic activity.

BL-1020 (perphenazine gamma-aminobutyrate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia, it's an ester of GABA and perphenazine, and pharmacologically it acts as a D2 antagonist and GABA agonist.

Field of Use
The Field of use of the Product for the prevention, diagnosis and treatment of all human diseases including for central nervous system diseases.

IPSCIO Record ID: 4271

License Grant
The Israeli Licensor signed an agreement to out-license the DOS program to the Licensee.  The Licensee was granted a license for patent rights and technology relating to the DOS program, and became responsible for all further development and commercialization activities and costs relating to our DOS program.
License Property
The Licensor's drug candidates and technologies are either in preclinical or clinical stages. The lead product candidates, Recombinant Human Erythropoietin (rHuEPO) and SAM-101, are planned for a Phase 2 clinical program and the Diversity Oriented Synthesis, or DOS program.
Field of Use
The Licensee is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HIV and HCV.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.